Dendritic cells loaded with tumor antigens and a dual immunostimulatory and anti-interleukin 10-specific small interference RNA prime T lymphocytes against leukemic cells

Translational Oncology

Volumn 2, Issue 4, 2009, Pages 242-246

  Iversen, Per O ^a,b   Semaeva, Elvira ^c   Sorensen, Dag R ^d   Wiig, Helge ^c   Sioud, Mouldy ^d  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER INFILTRATION; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG TARGETING; ENZYME ACTIVITY; GENE SILENCING; GENETIC TRANSFECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IN VITRO STUDY; LEUKEMIA CELL; NONHUMAN; RAT; T LYMPHOCYTE ACTIVATION;

EID: 77953448832     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09154     Document Type: Article

References (23)

1. el-Shami K and Smith BD (2008). Immunotherapy for myeloid leukemias: current status and future directions. Leukemia 22, 1658-1664.
2. Barrett AJ and Rezvani K (2007). Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clin Exp Immunol 148, 189-198.
3. Sioud M (2006). Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med 12, 167-176.
4. Kabelitz D, Wesch D, and Oberg HH (2006). Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol 26, 291-306.
5. Bruserud O (1998). IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Cytokines Cell Mol Ther 4, 187-198.
6. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
7. Sioud M (2004). Therapeutic siRNAs. Trends Pharmacol Sc 25, 22-28.
8. Sioud M (2005). Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348, 1079-1090.
9. Furset G and SioudM(2007).Design of bifunctional siRNAs: combining immuno-stimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun 352, 642-649.
10. Martens AC, van Bekkum DW, and Hagenbeek A (1990). The BN acute myelocytic leukemia (BNML) (a rat model for studying human acute myelocytic leukemia (AML)). Leukemia 4, 241-257.
11. Sioud M (2005). Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 348, 1079-1090.
12. Sioud M, Furset G, and Cekaite L (2007). Suppression of immunostimulatory siRNA-driven innate immune activation by 2?-modified RNAs. Biochem Biophys Res Commun 361, 122-126.
13. Antonov J, Goldstein DR, Oberli A, Baltzer A, Pirotta M, Fleischmann A, Altermatt HJ, and Jaggi R (2005). Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 85, 1040-1050.
14. Rehbinder C, Baneux P, Forbes D, van Herck H, Nicklas W, Rugaya Z, and Winkler G (1996). FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management, November 1995. Lab Anim 30, 193-208.
15. Iversen PO, SorensenDR, Tronstad KJ,GudbrandsenOA, Rustan AC, Berge RK, and Drevon CA (2006). A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia. Clin Cancer Res 12, 3525-3531.
16. Martens AC, Johnson RJ, Kaizer H, and Hagenbeek A (1984). Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells. Exp Hematol 2, 667-671.
17. Rolstad B and Fossum S (1987). Allogeneic lymphocyte cytotoxicity (ALC) in rats: establishment of an in vitro assay, and direct evidence that cells with natural killer (NK) activity are involved in ALC. Immunology 60, 151-157.
18. Semaeva E, Tenstad O, Bletsa A, Gjerde EA, and Wiig H (2008). Isolation of rat trachea interstitial fluid and demonstration of local cytokine production in lipopolysaccharide-induced systemic inflammation. J Appl Physiol 104, 809-820.
19. Blander JM and Medzhitov R (2006). On regulation of phagosome maturation and antigen presentation. Nat Immunol 7, 1029-1035.
20. Mortensen BT, Jensen PO, Helledie N, Iversen PO, Ralfkiaer E, Larsen JK, and Madsen MT (1998). Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 102, 458-464.
21. Klein G, Vellenga E, Fraaije MW, Kamps WA, and de Bont ES (2004). The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50, 87-100.
22. H1 response. Eur J Immunol 34, 1680-1687.
23. Chhabra A, Chakraborty NG, and Mukherji B (2008). Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35. Clin Immunol 126, 251-259.